alexa An Update on Pathogenesis and Treatment of Obesity | OMICS International | Abstract

Journal of Nutrition and Dietetics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

An Update on Pathogenesis and Treatment of Obesity

*Corresponding Author:

Copyright: © 0  . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

To read the full article Peer-reviewed Article PDF image


With fatness having adult to epidemic proportions, nearly half girls of procreative age square measure overweight and weighty and this is often a serious public ill health. because of unfavourable sex gland stimulation protocols, higher gonadotropin consumption and poor results most insurance corporations square measure reluctant to sponsor treatment for such patients .Since diet and exercise square measure inadequate treatments and bariatric surgery perhaps too extreme, treatment within the model of alternative chronic diseases by combination therapies has prompted the event of novel combination therapies like Qysmia (topiramate/phentermine)/Contrave (Bupropion SR/Naltrexone SR) that at the same time target multiple physiological pathways that regulate energy physiological condition to overwhelm endogenous counteractive mechanisms as opposed to use of monotherapies to take care of weight loss. The sole concern is that the slight risk of teratogenicity with topiramate therefore it's higher to use birth prevention whereas victimization topiramate/bupropionSR/naltrexoneSR. In weighty diabetics the GLP-1 receptor agonists like exenatide/liraglutide stay the medication of selection in combination with endocrine, whereas combination of lixisenatide and insulinglargine square measure within the pipeline for the long run.